Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
    • Real Estate
    • My Bing
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Calls Swift 'Kelce's wife'
Dropped by 18 brands
Horse killed, 4 hurt in crash
Cigna shares jump
Cardi B confirms split
California hiker rescued
To invest $1.5B in GoTo
AU to cut migrant intake
‘I am insecure’
Netanyahu speaks to Putin
Receives $5B+ buyout offer?
Suffers right hand fracture
Needs $46B for aid in '24
Stabbing at DC jail injures 3
Kids accept Nobel Prize
Defamation suit goes to trial
Has non-Hodgkin's lymphoma
US F-16 jet crashes in SK
Capitals defeat Blackhawks
To start military service
1-year, $4 million deal
Named Browns starting QB
Tanks enter Khan Younis
Priest stabbed to death
Bills beat Chiefs 20-17
Rangers beat Kings 4-1
Stephanie Pope as new COO
$43M+ overseas debut
UK sends 2 minehunters
James makes USC debut
Teases ‘White Lotus’ S3
Attends Milei's inauguration
Former Ky. governor dies
Golden Globe nominations
To buy CrownRock for $12B
Top search trends for 2023
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
4,120 results
Proactiveinvestors1mon
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...
The Motley Fool24d
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials. But that drug will need ...
BBC3d
Covid vaccine: Why are Australians cancelling AstraZeneca jabs?
AstraZeneca is the main vaccine offered in Australia but people increasingly don't want it Australian doctors have reported a surge in the number of people cancelling their vaccine appointments ...
Hosted on MSN1mon
AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill—As Weight Loss Drug Market Grows
AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight ...
Reuters27d
AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal of late stage trial
Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat ...
Hosted on MSN1mon
AstraZeneca CEO Pascal Soriot: Treatment of cancer in the last few years has been 'remarkable'
AstraZeneca CEO Pascal Soriot discusses Q3 earnings, oncology revenue, gene therapy treatments, what's to come for the company and the U.S. supply chain. Donald Trump Being Kicked off 2024 Ballot ...
MarketWatch1mon
AstraZeneca Shares Rise After Guidance Increase
Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines after beating ...
Morningstar7d
AstraZeneca PLC ADR AZN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Proactive Investors1mon
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Get the Bing App
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices